Amendments to the Claims

This listing of claims will replace all prior listings of claims in the application.

Listing of Claims

1. Canceled.

2. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 68 where the polymeric binder is selected from the group consisting of:

hydroxypropyl methylcellulose,
PVP,
hydroxypropyl cellulose,
methylcellulose,
hydroxyethylcellulose,
carbopol,
sodium carboxymethylcellulose.

3. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 68 wherein the polymeric binder is hydroxypropyl methylcellulose.

4. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 68 wherein the polymeric binder is PVP.

5. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 68 where the polymeric binder is present in the amount as follows for:

hydroxypropyl methyl cellulose of from about 5 to about 20%,

PVP from about 2 to about 15%,
hydroxypropyl cellulose from about 5 to about 20%,
methylcellulose from about 5 to about 20%,
hydroxyethylcellulose from about 5 to about 20%,
carbopol from about 3 to about 20%,
sodium carboxymethylcellulose from about 3 to about 20%.

6. (Currently Amended) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 68 where the superdisintegrant is croscarmellose sodium, sodium starch glycolate~~,~~ or L-hydroxypropyl cellulose.

7. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 68 where the superdisintegrant is present in an amount of from about 6 to about 35%.

8. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 7 where the superdisintegrant is present in an amount of from about 10 to about 30%.

9. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 68 which contains microcrystalline cellulose in an amount up to about 50%.

10. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to Claim 9 where the microcrystalline cellulose is selected from the group consisting of
microcrystalline cellulose coarse powder
microcrystalline cellulose medium powder and
microcrystalline cellulose 200.

11. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 9 where the microcrystalline cellulose is microcrystalline cellulose N.F. coarse powder.

12. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to Claim 9 where the microcrystalline cellulose is present in an amount of from about 10 to about 40%.

13. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 68 which contains lactose in an amount up to about 80%.

14. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 13 where the lactose is selected from the group consisting of lactose monohydrate spray process standard, lactose monohydrate, lactate anhydrous, lactose dihydrate, DMV lactose.

15. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 13 where the lactose is N.F. monohydrate spray process standard lactose.

16. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 13 where the lactose is present in an amount of from about 5 to about 20%.

17. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 68 which contains a flow agent in an amount up to 5%.

18. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 17 where the flow agent is selected from the group consisting of colloidal silicon dioxide and talc.

19. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 17 where the flow agent is colloidal silicon dioxide N.F.

20. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 17 where the flow agent is present in an amount from 0.25 to about 2%.

21. Canceled.

22. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 68 where the lubricant is selected from the group consisting of magnesium stearate and stearic acid.

23. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 22 where the lubricant is magnesium stearate.

24. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to claim 68 where the lubricant is present in the amount of 0.25 to about 2%.

25. Canceled.

26. (Previously Presented) A non-sustained release, non-chewable pharmaceutical tablet composition according to

claim 68 where the rapidly precipitating drug is present in an amount of from about 10 to about 40%.

27-33. Canceled.

34. (Previously Presented) A non-sustained release, non-chewable tablet composition according to Claim 3, wherein the polymeric binder is hydroxypropyl methylcellulose of from about 5 to about 20%.

35. Canceled.

36. (Currently Amended) A non-sustained release, non-chewable tablet composition according to claim ~~69~~68, wherein the mixing is accomplished in a high shear mixer.

37-67. Canceled.

68. (Currently Amended) A non-sustained release, non-chewable tablet composition comprising

_____(a) a rapidly precipitating drug which is a fairly soluble or highly soluble salt form of a poorly soluble free base or free acid that is prone to supersaturation when introduced in water or simulated physiological fluid at body temperature, and more than 90% of it precipitates out within 60 min after coming into contact with said water or simulated physiological fluid at body temperature, with the proviso that the drug is not delavirdine mesylate, is the sole active pharmaceutical ingredient in said composition and is present in an amount from about 5 to about 60%;

_____(b) a polymeric binder in an amount from about 2 to about 25%;

_____(c) a superdisintegrant in an amount from about 6 to about 40%; and

_____(d) a lubricant present in an amount up to about 5% , and wherein the rapidly precipitating drug, polymeric

binder, superdisintegrant and lubricant are mixed and compressed into a tablet without heating, solvent or grinding.

69. (Canceled)

70. (Currently Amended) A non-sustained release, non-chewable tablet composition ~~comprising (a) a rapidly precipitating drug with the proviso that the rapidly precipitating drug is the sole active pharmaceutical ingredient in said composition and is present in an amount from about 5 to about 60%; (b) a polymeric binder in an amount from about 2 to about 25%; (c) a superdisintegrant in an amount from about 6 to about 40%; and (d) a lubricant in an amount up to about 5%,~~ according to claim 71, wherein the rapidly precipitating drug is selected from clindamycin hydrochloride, clonidine hydrochloride, diphenhydramine hydrochloride, fluphenazine hydrochloride, hydromorphone hydrochloride, naloxone hydrochloride, oxytetracycline hydrochloride, phenylephrine hydrochloride, pheniramine maleate, tetracycline hydrochloride, verapamil hydrochloride, propoxyphene hydrochloride, hydrocodeine bitartrate, acyclovir sodium, albuterol sulfate, ampicillin sodium, benztropine mesylate, benzphetamine hydrochloride, bupivacaine hydrochloride, bupropin hydrochloride, clorphenamine maleate and chlorpromazine hydrochloride.

71. (New) A non-sustained release non-chewable tablet composition comprising

(a) a rapidly precipitating drug which is a fairly soluble or highly soluble salt form of a poorly soluble free base that is prone to supersaturation when introduced in water or simulated physiological fluid at body temperature, and more than 90% of it precipitates out within 60 min after coming into contact with said water or simulated physiological fluid at body temperature, with the proviso that the drug is not delavirdine mesylate, is the sole active pharmaceutical

ingredient in said composition and is present in an amount from about 5 to about 60%;

(b) a polymeric binder present in an amount of from 2 to about 25%;

(c) a superdisintegrant in an amount from about 6 to about 40%; and

(d) a lubricant present in an amount up to about 5%; and

wherein the rapidly precipitating drug, polymeric binder, superdisintegrant and lubricant are mixed and compressed into a tablet without heating, solvent or grinding.